This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, Biosimilars & Biotech. Check out our full report below:

Viridian Therapeutics Reports Topline Data from P-III (THRIVE-2) Study of Veligrotug to Treat Chronic Thyroid Eye Disease 

Read More: Viridian Therapeutics 

Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein Occlusion 

Read More: Regeneron 

Merck Discontinues Clinical Development Programs Evaluating Vibostolimab and Favezelimab for Various Indications 

Read More: Merck 

Merus Reports Dosing of First Patient in P-II Study Evaluating Petosemtamab in 3L+ mCRC 

Read More: Merus 

Roche Reports the P-IIb (PADOVA) Trial Data of Prasinezumab for Early-Stage Parkinson’s Disease 

Read More: Roche 

Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism 

Read More: Regeneron 

Dong-A ST Receives EC Approval for Imuldosa (Biosimilar, Stelara)

Read More: Dong-A ST

Merck Reports the CHMP’s Positive Opinion of Welireg (Belzutifan) for Von Hippel-Lindau (VHL) Disease-Associated Tumors and Previously Treated Renal Cell Carcinoma 

Read More: Merck 

Eli Lilly Reports the CHMP’s Positive Opinion of Omvoh (Mirikizumab) to Treat Moderate to Severe Active Crohn's Disease 

Read More: Eli Lilly 

GSK’s Jemperli (dostarlimab) Secures the US FDA’s Breakthrough Therapy Designation to Treat Rectal Cancer 

Read More: GSK 

Galderma’s Nemluvio (Nemolizumab) Secures the US FDA’s Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD) 

Read More: Galderma 

China's NMPA Approves Merck’s Keytruda Plus Chemotherapy as Neoadjuvant Treatment of NSCLC 

Read More: Merck 

GSK Reports the CHMP’s Positive Opinion of Jemperli Plus Chemotherapy for Indication Expansion to Endometrial Cancer 

Read More: GSK 

Merck Reports the US FDA’s BLA Acceptance of Clesrovimab to Protect Infants from RSV Disease 

Read More: Merck 

ViiV Healthcare Reports the CHMP’s Positive Opinion of Vocabria Plus Rekambys for HIV treatment 

Read More: ViiV Healthcare 

GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer 

Read More: GSK 

Eli Lilly Reports Kinsula (Donanemab-Azbt) Approval in China to Treat Early Symptomatic Alzheimer's Disease 

Read More: Eli Lilly 

Lantern Pharma's LP-184 Gains the US FDA’s Fast-Track Designation to Treat TNBC 

Read More: Lantern Pharma 

Pharma 

Candid Therapeutics Partners with EpimAb Biotherapeutics to Develop T-Cell Engagers for Autoimmune Disorders 

Read More: Candid Therapeutics and EpimAb Biotherapeutics 

Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets 

Read More: Gilead and Terray Therapeutics 

Abilita Therapeutics and Orion Collaborates to Advance Antibodies Development in Oncology and Pain 

Read More: Abilita Therapeutics and Orion 

Merck Join Forces with Hansoh Pharma to Develop HS-10535 

Read More: Merck and Hansoh Pharma 

Abbott Reports First-in-Human Leadless Pacing Procedures Using AVEIR Conduction System Pacing (CSP) Leadless Pacemaker 

Read More: Abbott 

AbbVie to Bolster its Immunology Pipeline Through the Acquisition of Nimble Therapeutics 

Read More: AbbVie and Nimble Therapeutics 

Celltrion Secures the CHMP’s Positive Opinion for Eydenzelt (Biosimilar, Eylea), Stoboclo & Osenvelt (Biosimilars, Prolia & Xgeva) and Avtozma (Biosimilar, RoActemra) 

Read More: Celltrion 

Bio-Thera Solutions and SteinCares Add Another Biosimilar, Expanding their Alliance 

Read More: Bio-Thera Solutions and SteinCares 

The US FDA Grants Approval to Celltrion's Steqeyma (Biosimilar, Stelara) 

Read More: Celltrion 

epiq Animal Health Collaborates with Interpath Global to Enhance the Joint Health Product Offering for Veterinarians 

Read More: epiq Animal Health and Interpath Global 

Related Post: PharmaShots Weekly Snapshots (December 09 – December 13, 2024)